There are more than 7,000 rare diseases worldwide, yet only about 5% currently have approved treatments. Most rare diseases require long-term therapy, leading to strong physician prescribing stickiness. Although patient populations are small, both willingness to pay and reimbursement support tend to be high.

The United States, the European Union, and China have all implemented accelerated review policies that continue to strengthen incentives for orphan drugs. Formulation innovation is expected to replace traditional chemical drug development as the mainstream pathway in many rare disease and specialty indications. Pediatric formulations, long-acting delivery systems, and non-invasive rapid-delivery technologies are emerging as key areas of focus. Globally, the rare disease and specialty market is projected to sustain 10–12% annual growth, making it one of the most resilient segments in the pharmaceutical industry.

Across rare disease and specialty therapeutics, there remains a significant lack of effective, safe, and patient-friendly treatment options, with formulation design and delivery experience often lagging clinical needs.

Aucta's existing focus on certain CNS subsegments—many of which are already classified as specialty or orphan indications—provides a natural extension for the company to expand into the broader orphan and specialty drug space.